Literature DB >> 8357780

Inhibitory effect of clentiazem (TA-3090), a new calcium antagonist, on balloon catheter-induced intimal thickening of rabbit aorta.

Y Saso1, A Ohtani, A Odawara, H Iwasaki, K Takashima, T Morita.   

Abstract

Male Japanese white rabbits were fed a restricted amount (100 g/head/day) of an atherogenic diet containing 0.2% cholesterol and 6% peanut oil during an 8-week experimental period. Atherosclerotic lesions, characterized by intimal thickening with lipid deposition, were produced by de-endothelialization of the rabbit aorta with a 4 F balloon catheter halfway through the experiment. Clentiazem (TA-3090), a new calcium antagonist, was administered at an oral dose of 30 mg/kg/day for 4 weeks starting on the day of deendothelialization. Clentiazem significantly depressed the intimal thickening without any effect on serum lipid levels. Clentiazem (1, 3, and 10 microM) significantly and dose-dependently inhibited the in vitro proliferation of smooth muscle cells that had been explanted from the neointima of the deendothelialized aorta. At a higher concentration, this drug markedly inhibited collagen-induced aggregation of rabbit platelets. Diltiazem also showed similar effects, but the effects of clentiazem were more potent than those of diltiazem. These results suggest that clentiazem exhibits an antiatherogenic effect, at least partly through prevention of smooth muscle cell proliferation in atheromatous lesions, in addition to its hypotensive action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8357780     DOI: 10.1007/bf00878516

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  36 in total

1.  Mechanism of action of clentiazem on human coronary artery and myocardium.

Authors:  H Narita; P H Zera; R Ginsburg
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  In-vitro study of the effect of clentiazem on rabbit aorta and on myocardium.

Authors:  H Narita; R Ginsburg
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

3.  Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110.

Authors:  D A Handley; R G Van Valen; M K Melden; R N Saunders
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

Review 4.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

5.  Failure of nifedipine to reduce atherogenesis in cholesterol-fed rabbits.

Authors:  M L Overturf; S A Smith
Journal:  Artery       Date:  1986

6.  Ineffectiveness of Ca2+-antagonists nicardipine and diltiazem on experimental atherosclerosis in cholesterol-fed rabbits.

Authors:  M Naito; F Kuzuya; K Asai; K Shibate; N Yoshimine
Journal:  Atherosclerosis       Date:  1984 May-Jun       Impact factor: 5.162

7.  Studies of the release from human platelets of the growth factor for cultured human arterial smooth muscle cells.

Authors:  L D Witte; K L Kaplan; H L Nossel; B A Lages; H J Weiss; D S Goodman
Journal:  Circ Res       Date:  1978-03       Impact factor: 17.367

8.  Long-lasting hypotensive and antihypertensive effects of a new 1,5-benzothiazepine calcium antagonist in hypertensive rats and renal hypertensive dogs.

Authors:  H Narita; S Murata; H Yabana; K Kikkawa; Y Sugawara; Y Akimoto; T Nagao
Journal:  Arzneimittelforschung       Date:  1988-04

9.  The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation.

Authors:  J Nilsson; M Sjölund; L Palmberg; A M Von Euler; B Jonzon; J Thyberg
Journal:  Atherosclerosis       Date:  1985-12       Impact factor: 5.162

10.  Suppression of experimental atherosclerosis by the Ca++-antagonist lanthanum. Possible role of calcium in atherogenesis.

Authors:  D M Kramsch; A J Aspen; C S Apstein
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.